

Eva Sedlackova

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2437030/eva-sedlackova-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

6,203
citations

16
h-index

30
g-index

30
ext. papers

7,436
ext. citations

6.9
avg, IF

4.9
L-index

#	Paper	IF	Citations
29	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet, The</i> , 2013 , 381, 805-16	40	1293
28	Lanreotide in metastatic enteropancreatic neuroendocrine tumors. <i>New England Journal of Medicine</i> , 2014 , 371, 224-33	59.2	1070
27	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2016 , 103, 153-71	5.6	712
26	ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. <i>Neuroendocrinology</i> , 2016 , 103, 172-85	5.6	612
25	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015 , 26, 1604-20	10.3	363
24	ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2016 , 103, 186-94	5.6	324
23	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8 years median follow-up. <i>Lancet Oncology, The</i> , 2011 , 12, 1101-8	21.7	298
22	ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. <i>Neuroendocrinology</i> , 2016 , 103, 125-38	5.6	264
21	Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5569-75	2.2	262
20	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 119-24	5.6	258
19	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 139-43	5.6	153
18	ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). <i>Neuroendocrinology</i> , 2016 , 103, 144-52	5.6	144
17	Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. <i>Endocrine-Related Cancer</i> , 2016 , 23, 191-9	5.7	142
16	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. <i>Annals of Oncology</i> , 2009 , 20, 1489-1498	10.3	136
15	The role of FDG-PET/CT in the detection of recurrent colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 779-84	8.8	88
14	Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. <i>Clinical Trials</i> , 2009 , 6, 272-87	2.2	31
13	Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. <i>Endocrine</i> , 2021 , 71, 502-513	4	11

12	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 295-306	4.4	8
11	Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4107-4107	2.2	7
10	Aleukemic granulocytic sarcoma with AML1/ETO fusion gene expression and clonal T cell populations. <i>Leukemia Research</i> , 2001 , 25, 1137-42	2.7	6
9	Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 233-233	2.2	4
8	Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. <i>Anti-Cancer Drugs</i> , 2020 , 31, 216-222	2.4	3
7	Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤5 vs. >65 years: Subgroup analyses from the CLARINET study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15177-e15177		3
6	Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15182-e15182	2.2	3
5	Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4104-4104	2.2	2
4	Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15180-e15180	2.2	2
3	Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15181-e15181	2.2	2
2	Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 367-367	2.2	2
1	Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15178-e15178	2.2	